Cargando…

Immune Checkpoint Inhibitors in Peripheral T-Cell Lymphoma

Peripheral T-cell lymphomas (PTCLs) are highly heterogeneous and present significant treatment challenges. Immune checkpoint therapies, such as PD-1 and CTLA-4 inhibitors, have significantly changed the clinical management paradigm of tumors. The roles of immune checkpoints in PTCL and related agent...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chen, Xi, Wu, Wanchun, Wei, Wenwen, Zou, Liqun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9086454/ https://www.ncbi.nlm.nih.gov/pubmed/35559250 http://dx.doi.org/10.3389/fphar.2022.869488

Ejemplares similares

Immune-mediated hepatitis induced by immune checkpoint inhibitors: Current updates and future perspectives
por: Liu, Zherui, et al.
Publicado: (2023)

Resistance mechanisms of immune checkpoint inhibition in lymphoma: Focusing on the tumor microenvironment
por: Zhang, Chunlan, et al.
Publicado: (2023)

Risk Factors, Incidence, and Prognosis of Thromboembolism in Cancer Patients Treated With Immune Checkpoint Inhibitors
por: Zou, Xue-lin, et al.
Publicado: (2021)

Drug therapy for myocarditis induced by immune checkpoint inhibitors
por: Wu, Yihao, et al.
Publicado: (2023)

Toxicity of Immune-Checkpoint Inhibitors in Hematological Malignancies
por: Hradska, Katarina, et al.
Publicado: (2021)

Clinical Insights Into Novel Immune Checkpoint Inhibitors
por: Lee, Jii Bum, et al.
Publicado: (2021)

Resistance to immune checkpoint inhibitors in gastric cancer
por: Liu, Kai, et al.
Publicado: (2023)

Immune Checkpoint Inhibitor Toxicity in Head and Neck Cancer: From Identification to Management
por: Wang, Haiyang, et al.
Publicado: (2019)

Adverse Events of Concurrent Immune Checkpoint Inhibitors and Antiangiogenic Agents: A Systematic Review
por: Gao, Ling, et al.
Publicado: (2019)

Hyperprogressive Disease in Cancers Treated With Immune Checkpoint Inhibitors
por: Shen, Pan, et al.
Publicado: (2021)

Potential role of gut microbes in the efficacy and toxicity of immune checkpoints inhibitors
por: Ma, Jingxin, et al.
Publicado: (2023)

Adverse Effects and Toxicity of Immune Checkpoint Inhibitors For Patients With Urothelial Carcinoma
por: Wang, Di, et al.
Publicado: (2021)

Cardiotoxicity associated with immune checkpoint inhibitors: Current status and future challenges
por: Gan, Lu, et al.
Publicado: (2022)

Loss of MHC-I antigen presentation correlated with immune checkpoint blockade tolerance in MAPK inhibitor-resistant melanoma
por: Yu, Jing, et al.
Publicado: (2022)

Hematological Side Effects of Immune Checkpoint Inhibitors: The Example of Immune-Related Thrombocytopenia
por: Calvo, Roser
Publicado: (2019)

Neurologic Toxicity of Immune Checkpoint Inhibitors: A Review of Literature
por: Albarrán, Víctor, et al.
Publicado: (2022)

The Strategies and Mechanisms of Immune Checkpoint Inhibitors for Brain Metastases in NSCLC
por: Li, Ji, et al.
Publicado: (2022)

Immune checkpoint inhibitors in osteosarcoma: A hopeful and challenging future
por: Zhang, Zeng, et al.
Publicado: (2022)

How to Monitor Cardiac Complications of Immune Checkpoint Inhibitor Therapy
por: Spallarossa, Paolo, et al.
Publicado: (2020)

Radiomics-guided checkpoint inhibitor immunotherapy for precision medicine in cancer: A review for clinicians
por: Zhou, Huijie, et al.
Publicado: (2023)

Prognosis of Lung Adenocarcinoma Patients With NTRK3 Mutations to Immune Checkpoint Inhibitors
por: Niu, Yuchun, et al.
Publicado: (2020)

Prognostic significance of the systemic immune-inflammation index in patients with extranodal natural killer/T-cell lymphoma
por: Hai, Tao, et al.
Publicado: (2023)

Unleashing the efficacy of immune checkpoint inhibitors for advanced hepatocellular carcinoma: factors, strategies, and ongoing trials
por: Yu, Jiahui, et al.
Publicado: (2023)

Catenin Alpha-2 Mutation Changes the Immune Microenvironment in Lung Adenocarcinoma Patients Receiving Immune Checkpoint Inhibitors
por: Wen, Yang, et al.
Publicado: (2021)

Cardiotoxicity Induced by Immune Checkpoint Inhibitors: A Pharmacovigilance Study From 2014 to 2019 Based on FAERS
por: Chen, Chenxin, et al.
Publicado: (2021)

Immune-Checkpoint Inhibitors in B-Cell Lymphoma
por: Armengol, Marc, et al.
Publicado: (2021)

Understanding the functional inflammatory factors involved in therapeutic response to immune checkpoint inhibitors for pan-cancer
por: Wu, Yanmeizhi, et al.
Publicado: (2022)

Immune Checkpoint in Glioblastoma: Promising and Challenging
por: Huang, Jing, et al.
Publicado: (2017)

Cardiac arrhythmias associated with immune checkpoint inhibitors: A comprehensive disproportionality analysis of the FDA adverse event reporting system
por: Wang, Feifei, et al.
Publicado: (2022)

Cisplatin Promotes the Efficacy of Immune Checkpoint Inhibitor Therapy by Inducing Ferroptosis and Activating Neutrophils
por: Zhou, Ziwei, et al.
Publicado: (2022)

Neutrophil-related genes predict prognosis and response to immune checkpoint inhibitors in bladder cancer
por: Yang, Rui, et al.
Publicado: (2022)

Immune Checkpoint Inhibitor-Associated Cardiotoxicity: Current Understanding on Its Mechanism, Diagnosis and Management
por: Zhou, Yu-Wen, et al.
Publicado: (2019)

Attitudes and Practices of Immune Checkpoint Inhibitors in Chinese Patients With Cancer: A National Cross-Sectional Survey
por: Zhang, Luping, et al.
Publicado: (2021)

Pancreatic Adverse Events Associated With Immune Checkpoint Inhibitors: A Large-Scale Pharmacovigilance Analysis
por: Zhang, Yue, et al.
Publicado: (2022)

Musculoskeletal adverse events induced by immune checkpoint inhibitors: a large-scale pharmacovigilance study
por: Liu, Hao, et al.
Publicado: (2023)

Safety and Efficacy of Therapeutic Cancer Vaccines Alone or in Combination With Immune Checkpoint Inhibitors in Cancer Treatment
por: Zhao, Jing, et al.
Publicado: (2019)

Immune Checkpoint Inhibitors and Immune-Related Adverse Drug Reactions: Data From Italian Pharmacovigilance Database
por: Ruggiero, Rosanna, et al.
Publicado: (2020)

Hematologic and lymphatic system toxicities associated with immune checkpoint inhibitors: a real-world study
por: Li, Na, et al.
Publicado: (2023)

The correlation between probiotic use and outcomes of cancer patients treated with immune checkpoint inhibitors
por: Zhang, Lilong, et al.
Publicado: (2022)

Pancreatic injury following immune checkpoint inhibitors: A systematic review and meta-analysis
por: Zhang, Tian, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_8u6ripqkljl07tbd79vr870sse